Does Tranexamic Acid Reduce the Need for Blood Transfusions in Patients Undergoing Hip Fracture Surgery?

• Status: Completed
• Trial end date: 2015-10-01
• Target enrollment: 0
• Participant gender: All

Summary

Does tranexamic acid improve the perioperative care of those patients treated surgically for hip fracture by decreasing the proportion of patients requiring transfusion and decreasing total perioperative bleeding.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Mayo Clinic
• Treatments: Tranexamic Acid

Criteria

Inclusion criteria

• AO/OTA (Orthopedic Trauma Association) fracture classification 31B

• Surgically treated with either hemiarthroplasty or total hip arthroplasty

• Acute fracture treated within 72 hours of injury

• Low energy isolated injury

• Age greater than 18 years old

Exclusion Criteria

• Transfusion received during admission, prior to surgery

• Creatinine clearance less than 30 mL/min

• History of unprovoked Venous Thromboembolism (VTE) and/or recurrent VTE

• Known history of Factor V Leiden, protein C/S deficiency, prothrombin gene mutation, anti-thrombin deficiency, anti-phospholipid antibody syndrome, lupus anticoagulant

• Pregnancy or breastfeeding (pregnancy tests will be performed on all patients of child-bearing potential)

• History of cerebrovascular accident (CVA), Myocardial infarction (MI), or VTE within the previous 30 days

• Coronary stent placement within the previous 6 months

• Disseminated intravascular coagulation

• Subarachnoid hemorrhage